Do you use off label olaparib in metastatic HER2 negative, BRCA2 positive breast cancer based on the OlympiAD data presented at ASCO?
Answer from: Medical Oncologist at Academic Institution
Both olaparib and talazoparib have presented phase III trials in patients with advanced breast cancer and mutations in BRCA1 or 2 demonstrating more than doubling of response rates and significant improvement in progression free survival with an associated improvement in QOL compared to treatment of...
Comments
Medical Oncologist at Sarah Cannon Cancer Institute at Menorah Medical Center I am glad the FDA approval allowed its use in the ...
I am glad the FDA approval allowed its use in the ...